Friends,
To understand why BCL-2 is such an attractive target in CLL and with the promise of venetoclax (ABT-199) hopefully coming soon, here is the very easy to digest nine minute lecture given by Dr. Michael Choi out of UCSD: cllsociety.org/2015/11/targ...
The introductory explanation on our website summarizes the background on Venetoclax’s downside, tumor lysis syndrome and includes links to two trials.
Stay strong.
We are all in this together.
Brian
EHA 2022: Outcomes Following Treatment With a Covalent BTK and BCL2 Inhibitor
The Impact of Diet on CLL
